Eli Lilly to acquire AtaiBeckley in deal worth up to $3.8 billion
MLex Summary: Eli Lilly and Co. has agreed to acquire AtaiBeckley Inc., a clinical-stage biopharma company developing therapeutics for mental health conditions, in a deal worth up to $3.8 billion. Under...To view the full article, register now.
Already a subscriber? Click here to view full article